Skip to main content
. Author manuscript; available in PMC: 2013 Oct 9.
Published in final edited form as: Ann Intern Med. 2011 Jul 19;155(2):69–79. doi: 10.7326/0003-4819-155-2-201107190-00002

Figure 3. Cost-effectiveness acceptability curves for all strategies, constructed from probabilistic sensitivity analyses.

Figure 3

For any given strategy, a higher willingness to pay per life-year gained meant a higher probability that the strategy was considered cost-effective. All strategies are compared with the referent strategy. IHC = immunohistochemistry; MSI = microsatellite instability.